Submitted:
25 April 2024
Posted:
26 April 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Chemicals and Reagents
2.2. Quantification of Cannabidiol and Caffeic acid by HPLC
2.3. Design and Preparation of the Microemulsion System
2.4. Physicochemical Characterization of Microemulsion
2.4.1. Conductivity
2.4.2. Droplet Size Distribution
2.4.3. Rheological Properties
2.4.4. Compatibility Studies
2.4.5. In Vitro Drug Release
2.5. Antioxidant Activity and Total Phenolics of the Microemulsion-Extract
3. Results and Discussion
3.1. Elaboration of the Pseudo-Ternary Phase Diagram And Design Of The Microemulsion System
3.2. Rheological Properties
3.3. Compatibility Studies by DSC
3.4. In Vitro Drug Release
3.5. Antioxidant Activity and Total Phenolics of the Microemulsion-Extract
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Baswan, S.M.; E Klosner, A.; Glynn, K.; Rajgopal, A.; Malik, K.; Yim, S.; Stern, N. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clin. Cosmet. Investig. Dermatol. 2020, 13, 927–942. [CrossRef]
- Battista, N.; Di Tommaso, M.; Bari, M.; Maccarrone, M. The endocannabinoid system: an overview. Front. Behav. Neurosci. 2012, 6, 9. [CrossRef]
- Kupczyk, P.; Reich, A.; Szepietowski, J.C. Cannabinoid system in the skin – a possible target for future therapies in dermatology. Exp. Dermatol. 2009, 18, 669–679. [CrossRef]
- Evers, A.; Lu, Y.; Duller, P.; van der Valk, P.; Kraaimaat, F.; van de Kerkhof, P. Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br. J. Dermatol. 2005, 152, 1275–1281. [CrossRef]
- Junaid, M.S.A.; Tijani, A.O.; Puri, A.; Banga, A.K. In vitro percutaneous absorption studies of cannabidiol using human skin: Exploring the effect of drug concentration, chemical enhancers, and essential oils. Int. J. Pharm. 2022, 616, 121540. [CrossRef]
- Eagleston, L.R.M.; Kalani, N.K.; Patel, R.R.; Flaten, H.K.; Dunnick, C.A.; Dellavalle, R.P. Cannabinoids in dermatology: a scoping review. Dermatol. Online J. 2018, 24, 24.
- Hashim, P.; Cohen, J.L.; Pompei, D.T.; Goldenberg, G. Topical cannabinoids in dermatology.. 2017, 100, 50–52.
- Grotenhermen, F.; Müller-Vahl, K. The Therapeutic Potential of Cannabis and Cannabinoids. Dtsch. Aerzteblatt Online 2012, 109, 495–501. [CrossRef]
- Freeman, T.P.; Hindocha, C.; Green, S.F.; Bloomfield, M.A.P. Medicinal use of cannabis based products and cannabinoids. BMJ 2019, 365, l1141. [CrossRef]
- del Río, C.; Millán, E.; García, V.; Appendino, G.; DeMesa, J.; Muñoz, E. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. Biochem. Pharmacol. 2018, 157, 122–133. [CrossRef]
- Pisanti, S.; Malfitano, A.M.; Ciaglia, E.; Lamberti, A.; Ranieri, R.; Cuomo, G.; Abate, M.; Faggiana, G.; Proto, M.C.; Fiore, D.; et al. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol. Ther. 2017, 175, 133–150. [CrossRef]
- Burstein, S. Cannabidiol (CBD) and its analogues: a review of their effects on inflammation. Bioorg. Med. Chem. 2015, 23(7), 1377-1385.
- Carrier, E.J.; Auchampach, J.A.; Hillard, C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression. Proc. Natl. Acad. Sci. 2006, 103, 7895–7900. [CrossRef]
- Bisogno, T.; Hanuš, L.; De Petrocellis, L.; Tchilibon, S.; E Ponde, D.; Brandi, I.; Moriello, A.S.; Davis, J.B.; Mechoulam, R.; Di Marzo, V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 2001, 134, 845–852. [CrossRef]
- Russo, E.B.; Burnett, A.; Hall, B.; Parker, K.K. Agonistic Properties of Cannabidiol at 5-HT1a Receptors. Neurochem. Res. 2005, 30, 1037–1043. [CrossRef]
- Atalay, S.; Jarocka-Karpowicz, I.; Skrzydlewska, E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants 2019, 9, 21. [CrossRef]
- Mlost, J.; Bryk, M.; Starowicz, K. Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action. Int. J. Mol. Sci. 2020, 21, 8870. [CrossRef]
- Soria-Lara, D.M.; Gaitán-Vélez, B.V.; Jiménez-Islas, H.; Miranda-López, R. El Sistema de Endocannabinoides como regulador de la lipogénesis y su posible modulación por la mangiferina. 2019, 30. [CrossRef]
- Millar, S.A.; Maguire, R.F.; Yates, A.S.; O’Sullivan, S.E. Towards Better Delivery of Cannabidiol (CBD). Pharmaceuticals 2020, 13, 219. [CrossRef]
- Makhakhe, L. Topical cannabidiol (CBD) in skin pathology – A comprehensive review and prospects for new therapeutic opportunities. South Afr. Fam. Pr. 2022, 64, 4–e4. [CrossRef]
- Zielińska, A.; Cano, A.; Andreani, T.; Martins-Gomes, C.; Silva, A.M.; Szalata, M.; Słomski, R.; Souto, E.B. Lipid-Drug Conjugates and Nanoparticles for the Cutaneous Delivery of Cannabidiol. Int. J. Mol. Sci. 2022, 23, 6165. [CrossRef]
- Mahmoudinoodezh, H.; Telukutla, S.R.; Bhangu, S.K.; Bachari, A.; Cavalieri, F.; Mantri, N. The Transdermal Delivery of Therapeutic Cannabinoids. Pharmaceutics 2022, 14, 438. [CrossRef]
- Rao, Y.; Li, R.; Liu, S.; Meng, L.; Wu, Q.; Yuan, Q.; Liang, H.; Qin, M. Enhanced bioavailability and biosafety of cannabidiol nanomicelles for effective anti-inflammatory therapy. Particuology 2022, 69, 1–9. [CrossRef]
- Crippa, J.A.; Guimarães, F.S.; Campos, A.C.; Zuardi, A.W. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Front. Immunol. 2018, 9, 2009. [CrossRef]
- Palmieri, B.; Laurino, C.; Vadalà, M. A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars. Clin. Ter. 2019, 170, e93–e99.
- Singh, K.; Nassar, N.; Bachari, A.; Schanknecht, E.; Telukutla, S.; Zomer, R.; Piva, T.J.; Mantri, N. The Pathophysiology and the Therapeutic Potential of Cannabinoids in Prostate Cancer. Cancers 2021, 13, 4107. [CrossRef]
- Urits, I.; Gress, K.; Charipova, K.; Habib, K.; Lee, D.; Lee, C.; Jung, J.W.; Kassem, H.; Cornett, E.; Paladini, A.; et al. Use of cannabidiol (CBD) for the treatment of chronic pain. Best Pr. Res. Clin. Anaesthesiol. 2020, 34, 463–477. [CrossRef]
- Ortega Serrano, A.E. Caracterización del aceite de cannabidiol utilizado como anticonvulsivante en el centro nacional de epilepsia. Bachelor's thesis. Publisher: Central University Ecuador UCE: Quito, Ecuador, 2017.
- Sheriff, T.; Lin, M.J.; Dubin, D.; Khorasani, H. The potential role of cannabinoids in dermatology. J. Dermatol. Treat. 2020, 31, 839–845. [CrossRef]
- Casiraghi, A.; Musazzi, U.M.; Centin, G.; Franzè, S.; Minghetti, P. Topical Administration of Cannabidiol: Influence of Vehicle-Related Aspects on Skin Permeation Process. Pharmaceuticals 2020, 13, 337. [CrossRef]
- Junaid, M.S.A.; Tijani, A.O.; Puri, A.; Banga, A.K. In vitro percutaneous absorption studies of cannabidiol using human skin: Exploring the effect of drug concentration, chemical enhancers, and essential oils. Int. J. Pharm. 2022, 616, 121540. [CrossRef]
- Petrosino, S.; Verde, R.; Vaia, M.; Allarà, M.; Iuvone, T.; Di Marzo, V. Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis. J. Pharmacol. Exp. Ther. 2018, 365, 652–663. [CrossRef]
- Vincenzi, C.; Tosti, A. Efficacy and Tolerability of a Shampoo Containing Broad-Spectrum Cannabidiol in the Treatment of Scalp Inflammation in Patients with Mild to Moderate Scalp Psoriasis or Seborrheic Dermatitis. Ski. Appendage Disord. 2020, 6, 355–361. [CrossRef]
- Morin, C.B.; Misery, L. Emerging Treatments and Novel Pathways in Pruritus. J. Cutan. Med. Surg. 2019, 23, 528–536. [CrossRef]
- Xu, D.H.; Cullen, B.D.; Tang, M.; Fang, Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Curr. Pharm. Biotechnol. 2020, 21, 390–402. [CrossRef]
- Chelliah, M.P.; Zinn, Z.; Khuu, P.; Teng, JM; Self-initiated use of topical cannabidiol oil for epidermolysis bullosa. Pediatr. Dermatol. 2018, 35(4), e224-e227.
- Kogan, A.; Garti, N. Microemulsions as transdermal drug delivery vehicles. Adv. Colloid Interface Sci. 2006, 123‒126, 369–385. [CrossRef]
- Lammari, N.; Louaer, O.; Meniai, A.H.; Fessi, H.; Elaissari, A. Plant oils: From chemical composition to encapsulated form use. Int. J. Pharm. 2021, 601, 120538. [CrossRef]
- Gibaud, S.; Attivi, D. Microemulsions for oral administration and their therapeutic applications. Expert Opin. Drug Deliv. 2012, 9, 937–951. [CrossRef]
- Perez-Roman, I.; Garcia-Rodriguez, J.J.; Kiekens, F.; Cordoba-Diaz, D.; Cordoba-Diaz, M. Enhanced Nematocidal Activity of a Novel Artemisia Extract Formulated as a Microemulsion. Nat. Prod. Commun. 2019, 14. [CrossRef]
- Ghosh, P.K.; Umrethia, M.L.; Majithiya, R.J.; Murthy, R.S. Preparación y caracterización físico-química de una microemulsión de macrogol-8-glicéridos de caprilocaproilo para la administración oral de fármacos. Ars. Pharma. 2004, 45(4), 353-372.
- Ustundag-Okur, N.; Gökçe, E.H.; Egrilmez, S.; Özer, .; Ertan, G. Novel Ofloxacin-Loaded Microemulsion Formulations for Ocular Delivery. J. Ocul. Pharmacol. Ther. 2014, 30, 319–332. [CrossRef]
- Arteaga, A.F. Preparación, caracterización y estabilidad de emulsiones y microemulsiones O/W. Ph D. Degree Thesis. Ed. University of Granada - Spain. 2006.
- Jabbari, M.; Daneshfard, B.; Emtiazy, M.; Khiveh, A.; Hashempur, M.H. Biological Effects and Clinical Applications of Dwarf Elder (Sambucus ebulus L): A Review. J. Evidence-Based Complement. Altern. Med. 2017, 22, 996–1001. [CrossRef]
- Shokrzadeh M.; Saravi SS. The chemistry, pharmacology and clinical properties of Sambucus ebulus: A review. J. of Med. Plants Research, 2010, 4(2): 095-103.
- Todorova, M. N.; Tasinov, O. B.; Pasheva, M. G.; Galunska, B. K.; Kiselova-Kaneva, Y. D. Sambucus ebulus extracts exhibit modulatory activity on inflammation and phagocytosis as revealed by changed gene expression in a model of LPS-treated J774A. 1 macrophage. Bilg. Chem. Commun., 2020.
- Pieri, V.; Schwaiger, S.; Ellmerer, E.P.; Stuppner, H. Iridoid Glycosides from the Leaves of Sambucus ebulus. J. Nat. Prod. 2009, 72, 1798–1803. [CrossRef]
- Ebrahimzad, M.; Nabavi, S. Antioxidant Activities of Methanol Extract of Sambucus ebulus L. Flower. Pak. J. Biol. Sci. 2009, 12, 447–450. [CrossRef]
- Farahani, A.M.; Aryanian, Z.; Memariani, Z.; Mozaffarpur, S.A.; Shirafkan, H. A Comparison of the Effect of Topical Preparation of Sambucus ebulus L. and Hydrocortisone on Hand Eczema: A Double-Blind Randomized Controlled Trial. J. Altern. Complement. Med. 2021, 27, 323–330. [CrossRef]
- Ahmadiani, A.; Fereidoni, M.; Semnanian, S.; Kamalinejad, M.; Saremi, S. Antinociceptive and anti-inflammatory effects of Sambucus ebulus rhizome extract in rats. J. Ethnopharmacol. 1998, 61, 229–235. [CrossRef]
- Ebrahimzadeh, M. A.; Mahmoudi, M.; Salimi, E. Anti-inflammatory activity of Sambucus ebulus hexane extracts. Fitoterapia, 2006, 77(2), 146-148.
- Yesilada, E. Evaluation of the anti-inflammatory activity of the Turkish medicinal plantSambucus ebulus. Chem. Nat. Compd. 1997, 33, 539–540. [CrossRef]
- Tasinov, O., Dincheva, I., Badjakov, I., Kiselova-Kaneva, Y., Galunska, B., Nogueiras, R., & Ivanova, D. Phytochemical Composition, Anti-Inflammatory and ER Stress-Reducing Potential of Sambucus ebulus L. Fruit Extract. Plants, 2021, 10(11), 2446.
- Gómez-Alonso, S.; García-Romero, E.; Hermosín-Gutiérrez, I. HPLC analysis of diverse grape and wine phenolics using direct injection and multidetection by DAD and fluorescence. J. Food Compos. Anal. 2007, 20, 618–626. [CrossRef]
- Vanti, G.; Grifoni, L.; Bergonzi, M.C.; Antiga, E.; Montefusco, F.; Caproni, M.; Bilia, A.R. Development and optimisation of biopharmaceutical properties of a new microemulgel of cannabidiol for locally-acting dermatological delivery. Int. J. Pharm. 2021, 607, 121036. [CrossRef]
- Marcotte, M.; Hoshahili, A.R.T.; Ramaswamy, H. Rheological properties of selected hydrocolloids as a function of concentration and temperature. Food Res. Int. 2001, 34, 695–703. [CrossRef]
- Ramírez-Moreno, E.; Cordoba-Díaz, M.; Sánchez-Mata, M.d.C.; Marqués, C.D.; Goñi, I. The addition of cladodes (Opuntia ficus indica L. Miller) to instant maize flour improves physicochemical and nutritional properties of maize tortillas. LWT 2015, 62, 675–681. [CrossRef]
- Bharate, S.S.; Bharate, S.B.; Bajaj, A.N. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. J. Excip. Food Chem. 2016, 1(3), 1131.
- Calderón, L.; Harris, R.; Cordoba-Diaz, M.; Elorza, M.; Elorza, B.; Lenoir, J.; Adriaens, E.; Remon, J.; Heras, A.; Cordoba-Diaz, D. Nano and microparticulate chitosan-based systems for antiviral topical delivery. Eur. J. Pharm. Sci. 2013, 48, 216–222. [CrossRef]
- Harrison, D.J.; Knutson, K. Accurate Determination of Skin Flux from Flow-Through Diffusion Cell Data. Pharm. Res. 1995, 12, 2003–2011. [CrossRef]
- Erdoğdu, F.; Şahmurat, F. MATHEMATICAL FUNDAMENTALS TO DETERMINE THE KINETIC CONSTANTS OF FIRST-ORDER CONSECUTIVE REACTIONS. J. Food Process. Eng. 2007, 30, 407–420. [CrossRef]
- Karadirek, .; Kanmaz, N.; Balta, Z.; Demirçivi, P.; Üzer, A.; Hızal, J.; Apak, R. Determination of total antioxidant capacity of humic acids using CUPRAC, Folin–Ciocalteu, noble metal nanoparticle- and solid–liquid extraction-based methods. Talanta 2016, 153, 120–129. [CrossRef]
- Flores, E. Extracción de Antioxidantes de las Bayas del Sauco (Sambucus nigra L. subsp. peruviana) con Ultrasonido, Microondas, Enzimas y Maceración para la obtención de Zumos Funcionales. 2017, 28, 121–132. [CrossRef]
- Acharya, D.P.; Hartley, P.G. Progress in microemulsion characterization. Curr. Opin. Colloid Interface Sci. 2012, 17, 274–280. [CrossRef]
- Numin, M.S.; Jumbri, K.; Ramli, A.; Borhan, N. Microemulsion Rheological Analysis of Alkaline, Surfactant, and Polymer in Oil-Water Interface. Processes 2020, 8, 762. [CrossRef]
- Vlad, R.A.; Sovany, T.; Kristó, K.; Ibrahim, Y.; Ciurba, A.; Aigner, Z.; Regdon, G. Structural and thermal analysis of cannabidiol orodispersible formulations. Farmacia (Bucharest), 2021, 69(3), 426-433.
- Segall, A.I. (2019). Preformulation: The use of FTIR in compatibility studies. JIAPS 2019, 4(3), 01-06.
- Sclafani, J.; Nightingale, J.; Liu, P.; Kurihara-Bergstrom, T. Flow-Through System Effects on in Vitro Analysis of Transdermal Systems. Pharm. Res. 1993, 10, 1521–1526. [CrossRef]
- Kubota, K.; Yamada, T. Finite Dose Percutaneous Drug Absorption: Theory and Its Application to In Vitro Timolol Permeation. J. Pharm. Sci. 1990, 79, 1015–1019. [CrossRef]
- Lu, G.W.; Gao, P. Chapter 3—Emulsions and Microemulsions for Topical and Transdermal Drug Delivery. In Handbook of Non-Invasive Drug Delivery Systems; Kulkarni, V.S., Ed.; William Andrew Publishing: Boston, MA, USA, 2010; pp. 59–94.
- Tóth, K.F.; Ádám, D.; Bíró, T.; Oláh, A. Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System. Molecules 2019, 24, 918. [CrossRef]
- Podczeck, F. Rheology of Pharmaceutical Systems. In Encyclopedia of Pharmaceutical Science and Technology, 4th Ed, Swarbrick, J. Ed; CRC Press; Boca Raton CA, USA, 2015.
- Grifoni, L.; Vanti, G.; Donato, R.; Sacco, C.; Bilia, A.R. Promising Nanocarriers to Enhance Solubility and Bioavailability of Cannabidiol for a Plethora of Therapeutic Opportunities. Molecules 2022, 27, 6070. [CrossRef]






| Starting composition S-CoS (1:1) / Oily phase (% w/w) |
Limit of microemulsion area S-CoS / O / W (% w/w) |
CBD content (% w/w) |
|---|---|---|
| 90 / 10 | 51 / 6 / 43 | 1.2 |
| 80 / 20 | 62 / 16 / 22 | 3.2 |
| 75 / 25 | 66 / 22 / 12 | 4.4 |
| 70 / 30 | 62 / 27 / 11 | 5.4 |
| 65 / 35 | 60 / 32 / 8 | 6.4 |
| 60 / 40 | 57 / 38 / 5 | 7.6 |
| 55 / 45 | 51 / 42 / 7 | 8.4 |
| Parameters | CBD OIL | Microemulsion-water | Microemulsion-extract |
|---|---|---|---|
| Mean apparent viscosity, (Pa.s) | 0.086 ± 0.004a | 0.176 ± 0.004b | 0.186 ± 0.002c |
| Consistency coefficient, K (Pa·sn) | 2.02 ± 1.70a | 2.92 ± 1.31a | 2.81 ± 0.20 a |
| Flow behavior index, n | 0.86 ± 0.21a | 0.88 ± 0.11a | 0.94 ± 0.04a |
| Determination coefficient R2 (%) | 99.07 | 99.64 | 99.92 |
| Hysteresis (Pa) | 0.072 ± 0.043a | 0.223 ± 0.078b | 0.313 ± 0.116 b |
| Sample ID | Reaction | Tonset(ºC) | Tendset(ºC) | Tpeak(ºC) | Enthalpy (J/g) |
|---|---|---|---|---|---|
| CBD crystalline | Endothermic Exothermic |
52 130 |
81 172 |
66 150 |
72.0 0.7 |
| Tg | 189 | 226 | 203 | - | |
| Exothermic Endothermic |
278 375 |
343 453 |
316 380 |
94.2 206.1 |
|
| CBD oil 20% | Exothermic Endothermic |
126 398 |
234 489 |
191 409 |
10.1 415.6 |
| Microemulsion | Endothermic Exothermic |
390 427 |
411 480 |
393 451 |
1.8 55.5 |
| Parameter | 20% CBD Oil | Microemulsion-Water (CBD) | Microemulsion-Extract (CBD) | Microemulsion-Extract (Caffeic acid) |
|---|---|---|---|---|
| SS-Intrinsic Flux - Japp (µg/cm2·h)1 Time to reach SS (TJmax) (h) Permeability coefficient Kp (cm/h) |
1604.403 0.648 0.0054 |
354.057 1.263 0.0079 |
306.122 1.468 0.0057 |
177.583 1.680 0.0002 |
| Cumulative amount vs. time profile curve fitting (SIMFIT monomolecular growth): | ||||
| Asymptote (mg) Release constant K1 (h-1) Goodness of fit: R-squared Durbin-Watson test statistic Shapiro-Wilks W |
13.998 ± 1.024 0.103 ± 0.036 0.9219 2.2946 0.965 |
2.112 ± 0.043 0.137 ± 0.007 0.9921 2.669 0.974 |
2.699 ± 0.112 0.096 ± 0.008 0.9518 1.4788 0.909 |
0.115 ± 0.014 0.0896 ± 0.022 0.7324 1.0568 0.952 |
| Antioxidant activity (µg eq. GA / µg dry extract) | Storage time | |
| t= 0 | t= 12 months | |
| TPC (Folin-Ciocalteau) µg eq. GA / µg dry extract | 0.0742 ± 0.0009a | 0.0712 ± 0.0006b |
| TAC (CUPRAC) µg eq. GA / µg dry extract | 0.0407 ± 0.0055a | 0.0437 ± 0.0135a |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).